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Background: Balloon aortic valvuloplasty (BAV) has often a compassionate rule in
the treatment of symptomatic and severe aortic stenosis (AS). Aim of this work was to
evaluate the clinical outcomes of BAV performed in emergency clinical setting.
Methods: Between September 2007 and September 2012, forty-two consecutive
emergency BAV were performed because of severe AS symptomatic for refractory
pulmonary edema (71%) or cardiogenic shock (29%).
Results: Most of the patients were female (60%) with mean age of 865 years and
Logistic Euroscore I of 4021%. Baseline echocardiographic data showed an aortic
valve area of 0.51.4 cm2 and a mean transvalvular gradient of 4614 mmHg, high
pulmonary hypertension (5015 mmHg) and left ventricular ejection fraction of
4114%. Coronary artery disease was present in 52%, with multivessel disease in
24% of the cases. During BAV, a coronary revascularization was performed in 26% of
the pts. An undersized balloon (20 mm) was used in 71% of cases. Drop of 3320
mmHg of peak aortic gradient was observed after BAV and in 57% of the procedures
one balloon inﬂation was enough. In-hospital death rate was 28%. All-cause death at 6
months was 45%. Transcatheter aortic valve replacement (TAVR) was performed in
56% of survival pts with a signiﬁcant improvement in clinical outcomes (NYHA class
II and no mortality at 6 months follow up in all pts).
Conclusions: Although high mortality rate was observed after BAV in emergency
clinical setting (refractory pulmonary edema or cardiogenic shock due to severe AS)
survival pts had a chance to be able to complete the treatment of AS by TAVR
procedure.
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Background: BNP is synthesized in cardiac ventricular tissue in response to increased
wall stress and is known to be elevated in patients with aortic stenosis, especially those
with clinical heart failure. We sought to characterize the timing and prognostic
signiﬁcance of changes in BNP levels after TAVR in the PARTNER I trial.
Methods: A total of 801 patients treated with transfemoral (TF) TAVR had BNP
levels determined at baseline, 1w, 6 m, 12 m, and 24 m after therapy. We further
divided patients into Group I (those with rising BNP levels at 1m) and Group II (those
with stable or falling BNP).
Results:Median Baseline BNP [IQR] was 619 [293, 1438], falling to 610 [289, 1342]
at 1w and 479 [238, 1006] at 1m. Thereafter, BNP levels remained stable at 6m (357
[175, 827]), 1y (341 [176, 729]), and 2y (346 [187, 782]). Mortality was increased at
6m, 1y, and 2y for patients with rising BNP (See ﬁgure). Similarly, repeat hospital-
ization was higher at 6m (18 vs 10%, p¼0.0008), 1y (24 vs 13%, p¼0.0002), and 2y
(40 vs 31%, p¼0.006). Patients in Group I were more likely to have moderate/severe
AR post-procedure (14.7 vs 9.3%, p¼0.03596). Moderate or severe mitral regurgi-
tation was similar between Group I and Group II at 1m echo (24 vs 18%, respectively,
p¼0.08), but was more common in Group I patients on the 6m echo (25 vs 16%,
p¼0.02).
Conclusions: BNP levels are elevated and tend to fall rapidly after TF-TAVR. Rising
BNP levels after TAVR are associated with a signiﬁcantly increased risk of death or
rehospitalization and post-procedure moderate/severe AR.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrTCT-774
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Background: Circulatory support (CS) may be needed during TAVR, but little is
known about the incidence, outcomes, and predictors of its use.
Methods: The study population included all patients in the PARTNER trial and
Continued Access Registry (CAR) that underwent TAVR. Patients that received CS
(intra-aortic balloon pump [IABP] or cardiopulmonary bypass [CPB]), either elective
pre-procedure or urgent intra-procedure, were compared to patients that did not
receive CS.
Results: Of the 2538 patients, 203 (8%) received support, including CPB (n¼133,
66%) or IABP (n¼70, 34%). Compared to those not receiving support, patients
receiving CS were more likely male (64% vs 51%, p< 0.0001), undergo transapical
access (81% vs 39%, p<0.0001), have prior CABG (60% vs 41%, p < 0.0001), lower
left ventricular EF (47 vs 53%, p<0.001), and moderate or severe mitral regurgitation
(28% vs 21%, p ¼ 0.03). The incidence of CS was higher in the CAR than in the
PARTNER trial (9% vs 5%), partly due to an increased proportion of transapical cases
(50% vs 20%, respectively). The use of circulatory support was associated with
greater procedural complications, including major vascular complications (17% vs
5%, p< 0.0001) and valve embolization (5% vs 0.5%, p<0.0001). CS was associated
with a signiﬁcantly higher 30 day all-cause mortality (25% vs 5%, p< 0.0001), and
was higher in patients that received CPB compared to IABP (32% vs 13%, p¼0.003).
The mortality difference between the CS and non-CS groups persisted at two years
(48% vs 28%, p< 0.0001). The speciﬁc indication for CS, elective pre-procedure or
urgent resulting from a complication, will be separately analyzed to determine the
effect on outcome.
Conclusions: The use of CS during TAVR is surprisingly frequent, associated with
procedural complications, and portends a higher early and late mortality. CS was used
more frequently in registry patients as compared to randomized trial patients. Iden-
tifying patients most likely to beneﬁt from CS may represent an opportunity to
improve outcomes.
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Background: Transcatheter aortic valve replacement (TAVR) can be performed via
different access routes and settings. The economic beneﬁts of TAVR over SAVR in
a variety of procedural settings are unclear. Our goal was to compare cost of TAVR byacts/POSTER/Aortic Valve Disease and Treatment B235
